Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2026-02-25

FDA Approved: SAXENDA — Supplemental Application (Novo Nordisk)

View source ↗

Summary

FDA approved a supplemental application for SAXENDA (liraglutide) submitted by Novo Nordisk.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SAXENDA (liraglutide)

Snippet

SUPPL AP for SAXENDA (LIRAGLUTIDE)